Single-cell transcriptomics identifies SOCS3+ exhausted T cells as a biomarker facilitating clear cell renal cell

Xiaoqin Jiang1, Yifan Xu1, Zhenjie Wu1

  • 1Department of Urology, Shanghai Changhai Hospital, Naval Medical University, 168 Changhai Rd, Shanghai, 200433, China.

PubMed

Insights

Exhausted T cells, specifically SOCS3+ exhausted T cells, drive clear cell renal cell carcinoma (ccRCC) progression and immunotherapy resistance. These cells are identified as a key prognostic biomarker for ccRCC patients.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Clear cell renal cell carcinoma (ccRCC) is a common kidney cancer with few early symptoms.
  • Advanced ccRCC can respond to immunotherapy, but mechanisms of progression are not fully understood.
  • Exhausted T cells are implicated in tumor progression and immune evasion.

Purpose of the Study:

  • To investigate the role of exhausted T cells in ccRCC progression using single-cell transcriptomics.
  • To identify prognostic biomarkers for ccRCC.
  • To elucidate the mechanisms of immune evasion driven by exhausted T cells.

Main Methods:

  • Single-cell transcriptomic data re-analysis using dimensionality reduction and clustering.
  • Differential gene expression analysis to identify prognostic genes.
  • Construction and validation of a nomogram prediction model.
  • Gene Ontology and Reactome pathway enrichment analysis.
  • Ligand-receptor interaction profiling for cell-cell communication analysis.

Main Results:

  • Nine distinct cellular populations were identified, with SOCS3+ exhausted T cells showing significant prognostic relevance.
  • A nomogram model using SOCS3 and N4BP1 accurately stratified patients into risk groups.
  • SOCS3+ exhausted T cells interact with myeloid cells via the MIF signaling pathway.
  • These cells were found to promote resistance to cytotoxic killing.

Conclusions:

  • SOCS3+ exhausted T cells promote tumor resistance to cytotoxic killing in ccRCC.
  • SOCS3+ exhausted T cells are a robust prognostic biomarker for ccRCC patients.
  • Understanding these cells offers potential therapeutic targets for improving ccRCC treatment outcomes.